Fellowship ​

Professor Kaye is an internationally recognised clinician-scientist working who has made a major contribution to the understanding and treatment of heart failure. Prof Kaye is an NHMRC Senior Principal Research Fellow at Baker IDI and an active senior Cardiologist in the Heart Failure- Transplant Unit at the Alfred Hospital, Melbourne. Professor Kaye holds numerous research grants including an NHMRC Program Grant, NHMRC Centre of Research Excellence Grant and an NHMRC Development Grant, with cumulative competitive grant support in excess of $44M. Prof Kaye’s translational research has also created a substantial portfolio of intellectual property that has led to the invention of novel medical devices and pharmacological therapies, including 2 spin-out companies that have raised >$100M.

Professor Stephen Jane is Head of Central Clinical School, Professor of Medicine, Monash University, Director of Research, Alfred Health and Acting Head of Clinical Haematology and The Australian Centre for Blood Diseases. He was previously a Principal Research Fellow of the NHMRC, Professor of Medicine, University of Melbourne and Director of the Bone Marrow Research Laboratories, Royal Melbourne Hospital. His research interests centre on transcriptional regulation in blood and skin, and he currently holds six NH&MRC grants and international competitive funding. He has published over 100 papers including articles in Science, Nature Medicine, Cancer Cell and Developmental Cell.

Professor Douglas Hilton is an expert in the field of molecular regulation of blood cell production and cytokine signal transduction. His creative discovery spans four distinct areas of molecular haematology: leukaemia inhibitory factor, cytokine receptor family, suppressors of cytokine signalling, and identification of haematopoietic regulators through a large-scale forward mutagenesis screen. He has applied these discoveries to real health outcomes through industry collaborations. Hilton is well known for his leadership in public awareness campaigns for health and medical research and in government lobbying for more effective funding policy. He is President-elect of AAMRI and a member of the MRFF Action Group.

Professor Len Harrison was among the first to characterise the insulin receptor, including its clinical relevance. He inaugurated Australian research into the pathogenesis, pre-clinical diagnosis and prevention of type 1 diabetes (T1D). He discoveries include: mechanisms of pancreatic beta-cell destruction, the primacy of insulin as an autoantigen, protective immune tolerance induced by insulin, T-cell epitopes in pancreatic beta-cell autoantigens; insulin resistance as a risk factor for T1D and the CD52-Siglec system of immune regulation. Following ‘proof-of-concept’ studies in mice, he has conducted a series of trials, currently Phase 2b, of a nasal insulin vaccine to prevent T1D.